Glaucoma Reports

The “2026 European Five Ophthalmic Market Report” delivers a comprehensive, data-driven view of Western Europe’s five largest ophthalmic markets—France, Germany, Italy, Spain, and the United Kingdom—across 11 key submarkets. The report analyzes current market dynamics, identifies the trends shaping demand, and provides clear forecasts through 2031 to support strategic planning and competitive positioning. 

In addition, the report includes detailed disease prevalence forecasts, treatment and procedure volume analysis, emerging technology assessment, and in-depth profiles of leading competitors to provide a complete picture of how these major European markets are evolving and where the strongest opportunities are expected to emerge. 

The “2026 Glaucoma Pharmaceuticals Market Report” provides a data-driven view of the global and regional glaucoma drug markets, highlighting the trends and competitive forces shaping future growth. The report includes forecasts through 2031 across all major therapy classes, including prostaglandins (branded and generic), beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combinations, NO-donating compounds, and Rho-kinase inhibitors. 

In addition, the report examines a robust development pipeline of over 30 drug candidates and profiles 23 leading companies, providing insight into product portfolios, strategic positioning, and future outlook. 

The "2025 India Ophthalmic Market Report" delivers a comprehensive analysis of India’s ophthalmic market, highlighting key trends, competitive dynamics, and factors shaping future growth. The report includes forecasts for disease prevalence, procedure volumes, and technology adoption across diagnostic equipment, lasers, cataract, refractive, cornea, glaucoma, retina, dry eye, surgical instruments, and single-use surgical devices. 

Profiles of 30 leading competitors provide insight into product portfolios, strategic positioning, and market outlook. 

The Ophthalmic Market Trends: Quarterly US Glaucoma Editions deliver essential, data-driven insights into the US glaucoma surgery market. These reports, based on quarterly surveys of glaucoma surgeons, provide a comprehensive analysis of key metrics such as patient diagnoses, treatment regimens, medication usage, surgical procedure volumes, and emerging trends in MIGS, canal-based procedures, and investigational treatments. With in-depth trend analysis, full-year forecasts, and year-over-year comparisons, these editions equip you with the latest information on product adoption, market share, and treatment strategies, ensuring you make informed, strategic decisions in the glaucoma treatment landscape.

Market Scope’s “2025 Ophthalmic Diagnostic Equipment Market Report” is the definitive resource for understanding the global ophthalmic diagnostic landscape. This edition delivers in-depth analysis of the current markets for diagnostic equipment in cataract and refractive surgery, refracting and screening instruments, and emerging technologies. It also provides five-year global forecasts, along with regional and economic analyses across the US, Western Europe, Japan, other wealthy nations, China, India, Latin America, and developing markets worldwide. 

The report considers more than 800 devices from 115 manufacturers, covering technologies that span corneal topographers, anterior eye scanners, biometers, tonometers, fundus cameras, perimeters, refractors, slit lamps, and advanced microscopy systems. 

Each section includes market sizing, pricing trends, competitor market share, installed equipment base, and company profiles, giving manufacturers, investors, and eye care providers the actionable intelligence needed to navigate competitive dynamics, plan strategic growth, and anticipate technological innovation.  

The “2025 Glaucoma Surgical Device Market Report” provides a data-driven analysis of the global market for glaucoma surgical devices, offering comprehensive coverage of current technologies, innovation pipelines, competitive positioning, and growth opportunities by region. 

The report examines global glaucoma prevalence and treatment trends. It details the full spectrum of commercialized devices—including microstents, subconjunctival shunts, canal surgery devices, and tube shunts—and evaluates the pipeline of investigational products that are poised to improve outcomes and drive future adoption. 

Market demand is forecast in both units and dollars through 2030, with detailed segmentation by device category, procedure type, and region. Competitive analysis includes market share estimates, plans for product adoption, and detailed profiles of 29 leading and emerging companies, highlighting their products, strategic positioning, and outlook in this rapidly evolving segment. 

The 2025 China Ophthalmic Market Report delivers a comprehensive analysis of China’s rapidly evolving ophthalmic sector, analyzing the demographic trends and economic conditions that will shape the future of the market. The report offers deep insights into disease prevalence, highlights commercialized products and promising pipeline assets, and forecasts unit demand, sales revenue, and market performance through 2030. Competitive dynamics are thoroughly analyzed across product categories, and the report provides detailed profiles of 32 major competitors, their product portfolios, strategic positions, and future outlooks.  

Market Scope’s 2025 Glaucoma Disease Model offers extensive country-level prevalence data and five-year forecasts for glaucoma by type and by age group for all countries with a population over a million.

This proprietary model takes into consideration the latest clinical research and demographic projections on a global scale and can be customized by geography and disease category to meet clients’ diverse needs. Disease models can be used to evaluate target markets for clinical-stage and commercial-stage products and gain insights into the volume and demographics of diseased populations.

The “2024 Ophthalmic Landscape Report” offers a high-level analysis of the ophthalmic market by region and subspecialty and forecasts market performance of nine product categories through 2029. The report analyzes important trends, reviews key factors for future success, comprehensively details the competitive landscape in ophthalmology, and compares the ophthalmic sector across health care and other related markets. 

The “2025 Glaucoma Pharmaceuticals Market Report” analyzes the global and regional markets for glaucoma pharmaceuticals, identifying important trends and key factors for future success. The report provides forecasts through 2030 for branded prostaglandins, generic prostaglandins, beta blockers, carbonic anhydrase inhibitors, alpha agonists, fixed combo drugs, NO-donating compounds, and Rho-kinase inhibitors. The report also extensively discusses pipeline products, covering over 30 drug candidates that are currently under development. Additionally, 25 glaucoma pharmaceutical companies are profiled, with discussion of their products, strategic market position, background, and outlook.